adrenergic agonist

(redirected from adrenergic receptor agonist)

adrenergic agonist

A family of agents which have adrenaline-like effects, acting directly or indirectly on any of the five G-protein-coupled adrenergic receptors: apha1, alpha2, beta1, beta2, beta3.

Actions of adrenergic agonists
alpha1 receptors: Activate phospholipase C (via Gq), increasing protein kinase C activity.
alpha2: receptors Inhibit adenylate cyclase (via G1), decreasing protein kinase A activity.
beta receptors: Activate adenylate cyclase (via Gs), increasing protein kinase A activity.

adrenergic agonist

Any of a group of therapeutic agents, e.g. epinephrine, that mimic or stimulate the sympathetic nervous system.
See also: agonist

sympathomimetic drugs 

Drugs that produce an effect similar to that obtained by stimulation of the sympathetic nervous system. Some of these predominantly act on the adrenergic alpha-receptors (e.g. noradrenaline (norepinephrine)), while others act on the adrenergic beta-receptors (e.g. isoproterenol). Others have little direct effect on the adrenergic receptors but enhance the release of natural catecholamine from the sympathetic nerve terminals (e.g. amphetamine, phenylpropanolamine). Sympathomimetic drugs are used (1) in the treatment of open-angle glaucoma by decreasing aqueous humour secretion and increase the outflow through the trabecular meshwork thus reducing the intraocular pressure (e.g. adrenaline (epinephrine), apraclonidine, dipivefrine hydrochloride, brimonidine tartrate), (2) dilate the pupil without affecting accommodation (e.g. phenylephrine) and (3) constrict conjunctival blood vessels (e.g. naphazoline, tetrahydrozoline). Syn. adrenergic agonist; adrenergic stimulating agent. See alpha-adrenergic agonist; mydriatic.

ad·re·ner·gic ag·o·nist

(adrĕ-nĕrjik agŏ-nist)
An agent capable of combining with receptors to initiate actions of or like epinephrine.
See: agonist
See also: epinephrine
References in periodicals archive ?
Developed by scientists at NTU, the new type of skin patch contains hundreds of micro-needles, each of them thinner than a human hair, which are loaded with the drug beta-3 adrenergic receptor agonist or another drug called triiodothyronine, containing thyroid hormone T3.
INTUNIV is a selective alpha-2A adrenergic receptor agonist. As Shire's global head of research and development, Philip J Vickers PhD, noted, its approval "marks a significant advance in the treatment of ADHD in children and adolescents in Japan, who may benefit from a new treatment option."
Albuterol (b2 adrenergic receptor agonist) and budesonide have an important place in the relief of acute and chronic pulmonary problems in children.
Dexmedetomidine is an [[alpha].sub.2] adrenergic receptor agonist, with studies demonstrating a high ratio of [[alpha].sub.2]/[[alpha].sub.1]-activity (1620: 1) [3].
The extended-release form of the drug, a selective alpha-2A adrenergic receptor agonist, previously had been approved as monotherapy for treating ADHD.
The extended-release form of the drug is a selective alpha-2A adrenergic receptor agonist and was first approved for the treatment of hypertension in 2002, and for ADHD in 2007.
Law enforcement personnel with the New Jersey State Police responded to the outbreak and tested samples of the heroin involved; the presence of clenbuterol, a [[beta].sub.2] adrenergic receptor agonist, was reported.
Flucatisone is a corticosteroid and salmeterol is a selective long-acting beta-2 adrenergic receptor agonist. This DPI is available as Advair Diskus 100/50[R], Advair 250/50[R], and Advair 500/50[R], which represent the flucatisone dose (100 mcg, 250 mcg, or 500 mcg)/salmeterol dose (50 mcg) per inhalation.
INTUNIV is a 'selective 2A adrenergic receptor agonist', firstly approved as a drug for ADHD with this mechanism of action, and INTUNIV is a non-central nervous system stimulant that is to be administered once daily and has been approved as a drug for ADHD in pediatric patients (6 to 17 years old) in 36 countries including Japan (as of March 2018).
The company added that the Phenylephrine Hydrochloride Ophthalmic Solution, USP, is an alpha-1 adrenergic receptor agonist indicated to dilate the pupil.
The first agent is mirabegron (Myrbetriq), which is the first FDA-approved beta-3 adrenergic receptor agonist. This agent works by relaxing the detrusor smooth muscle during the storage phase of the bladder fill-void cycle.

Full browser ?